Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China-Reference-Cited by-同舟云学术

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

Published:2007-05 Issue:5 Volume:2 Page:430-439
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Wu Yi-Long,Zhong Wen-Zhao,Li Long-Yun,Zhang Xiao-Tong,Zhang Li,Zhou Cai-Cun,Liu Wei,Jiang Bin,Mu Xin-Lin,Lin Jia-Ying,Zhou Qing,Xu Chong-Rui,Wang Zhen,Zhang Guo-Chun,Mok Tony

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference55 articles.

1. Estimation and projection of the national profile of cancer mortality in China: 1991-2005;Yang;Br J Cancer,2004

2. Cancer statistics, 1999;Landis;CA Cancer J Clin,1999

3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer;Scagliotti;J Clin Oncol,2002

5. The biology of epidermal growth factor receptor in lung cancer;Scagliotti;Clin Cancer Res,2004

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical data;Translational Lung Cancer Research;2024-06

2. Evaluation of the Efficacy of OSU-2S in the Treatment of Non-Small-Cell Lung Cancer and Screening of Potential Targets of Action;Pharmaceuticals;2024-05-01

3. A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced NSCLC patients;Translational Lung Cancer Research;2023-07

4. Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study;Current Oncology;2022-12-22

5. B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors;World Journal of Surgical Oncology;2022-05-20